Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

Yucai Wang 1, Grzegorz S. Nowakowski 1, Michael L. Wang 2 and Stephen M. Ansell 1*

Abstract

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies.

Background

Hodgkin lymphoma (HL) accounts for approximately 10% of lymphomas. It is estimated that there will be 8500 new cases of HL and 1050 deaths from this disease in the USA in 2018 [1]. The age at diagnosis shows a bimodal distribution, with one peak between 15 and 34 and the other after 60 [2]. Pathologically, HL is characterized by clonal malignant Hodgkin and Reed-Sternberg (HRS) or variant cells, which reside in an extensively inflammatory tumor microenvironment. Based on morphology and HRS cell phenotypes, HL can be divided into classical HL (cHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), with the latter accounting for about 5% of Hodgkin lymphoma cases. In cHL, the characteristic HRS cells are giant, mononucleated (Hodgkin cells) or multinucleated (Reed-Sternberg cells), with prominent eosinophilic inclusion-like nucleoli. They are typically positive for CD15 and CD30. The HRS cells produce various cytokines, through which they interact with surrounding immune cells to drive their own proliferation and survival and regulate the host response. In NLPHL, the HRS variant cells are termed lymphocyte-predominant (LP) cells and are typically negative for CD15 and CD30 but positive for CD20. The treatment strategies for cHL and NLPHL differ due to distinct biology.

With standard frontline chemotherapy such as ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) and radiotherapy when indicated, the majority of cHL patients can be cured. However, approximately 10% of early-stage and 30% of advanced stage cHL patients experience disease relapse after frontline therapy or have refractory disease that fails to respond to frontline therapy, and only half of them can be cured with salvage chemotherapy followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) [2].

Several novel therapies for cHL have emerged in recent years. The two major targets are CD30, which is expressed by HRS cells, and programmed cell death protein 1 (PD-1), the receptor for programmed death-ligand 1 (PD-L1) and PD-L2 which are almost universally overexpressed in HRS cells due to chromosome 9p24.1 amplification [3]. The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 inhibitors nivolumab and pembrolizumab are approved by the United States Food and Drug Administration (FDA) and have significantly changed the landscape of cHL management. Their mechanisms of action are shown in Fig. 1. Agents targeting the JAK/STAT and PI3K/Akt/mTOR pathways, histone acetyltransferase (HDAC) inhibitors and immunomodulatory drugs (IMiDs) have also been investigated, with some promising results demonstrated in early-phase clinical studies [4]. In this article, we review the advances in CD30- and PD-1-targeted therapies in cHL, with a focus on major...
completed or ongoing studies on brentuximab vedotin, nivolumab, and pembrolizumab. Of note, although “classical HL” was not explicitly specified in some of these studies, all the data should be on cHL, given the CD30 expression and 9p24.1 amplification in cHL and distinct management approaches of cHL and NLPHL.

**CD30-targeted therapy**

**Monoclonal antibodies and mAb-immunotoxin conjugates**

CD30 is a member of the tumor necrosis factor (TNF) receptor superfamily. In healthy individuals, its expression is restricted to a small fraction of activated B and T cells. In cHL, CD30 is highly expressed on HRS cells and is an ideal therapeutic target. However, the activity of several unconjugated anti-CD30 monoclonal antibodies (mAbs) in cHL was minimal. In an early study, a CD30 mAb Ber-H2 demonstrated excellent in vivo targeting of HRS cells but did not have an antitumor effect in six patients treated [5]. In a phase 1/2 study, a fully human CD30 mAb MDX-60 showed only limited activity against HL, with 2 complete responses (CR) and 2 partial responses (PR) in 63 patients [6]. In another phase 1 study of the chimeric mAb SGN-30 (cAC10), no objective response was seen in 21 HL patients [7]. In a phase 2 study, SGN-30 did not result in any objective response in HL either [8]. The reason for the poor activity of these unconjugated anti-CD30 mAbs in cHL is unclear. One potential mechanism may be insufficient cell killing following CD30 binding. We suspect that the antibody-dependent cell killing mechanisms such as antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis are compromised in these heavily pretreated HL patients with immunosuppression.

On the other hand, mAb-immunotoxin conjugates seemed to have some limited activity in HL. In an early study, a mAb-immunotoxin conjugate Ber-H2-saporin resulted in tumor reduction in all four treated patients, although duration of response was limited (up to 10 weeks) [9]. In a phase 1 study, Ki-4.dgA, a conjugate of CD30 mAb and deglycosylated ricin A-chain, produced 1 PR and 1 minor response (MR) in 15 HL patients [10].

**Brentuximab vedotin**

*Therapy for relapsed or refractory disease*

The breakthrough in CD30-targeted therapy in HL came with the development of brentuximab vedotin (SGN-35), an ADC consisting of chimeric CD30 mAb brentuximab (cAC10) and an antimitotic agent monomethyl auristatin E (MMAE) (Table 1). In early-phase clinical trials, brentuximab vedotin demonstrated impressive single-agent activity in CD30-positive hematological malignancies including HL and anaplastic large-cell lymphoma (ALCL). In the first phase 1 dose-escalation study with doses ranging from 0.1 to 3.6 mg/kg every 3 weeks, the maximum tolerated dose (MTD) was 1.8 mg/kg. In 42 patients with HL, the objective response rate (ORR) was 36%, with 9 CR and 6 PR. For the 12 patients who were treated at the MTD, the ORR was 50%, with 4 CR (33%) and 2 PR.
| Study                          | Phase | N  | Setting                          | Treatment                                                                 | Efficacy results                                                                                     |
|-------------------------------|-------|----|----------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Younes et al. 2010 [11]       | 1     | 42 | Relapsed or refractory           | Bv 0.1 to 3.6 mg/kg Q3W MTD 1.8 mg/kg                                     | All patients:                                                                                       |
|                               |       |    |                                  |                                                                           | ORR 36% (CR 21%, PR 14%) MTD only (n = 12): ORR 50% (CR 33%, PR 17%)                                |
| Fanale et al. 2012 [12]       | 1     | 38 | Relapsed or refractory           | Bv 0.4 to 1.4 mg/kg on days 1, 8, and 15 of each 28-day cycle MTD 1.2 mg/kg | All evaluable (n = 35): ORR 54% (CR 29%, PR 26%) MTD only (n = 12): ORR 58% (CR 25%, PR 33%)      |
| Younes et al. 2012 [14-16]    | 2     | 102| Relapsed or refractory after ASCT| Bv 1.8 mg/kg Q3W for up to 16 cycles                                     | ORR 75% (CR 34%, PR 40%) Medial PFS 20.5 months (CR patients) 3-year follow-up: Medial PFS 9.3 months, median OS 40.5 months |
|                               |       |    |                                  |                                                                           | 5-year follow-up:                                                                                   |
|                               |       |    |                                  |                                                                           | 5-year PFS rate 22%, 5-year OS rate 41%                                                            |
| O'Connor et al. 2018 [19]     | 2     | 37 | Relapsed or refractory           | Bv 1.8 mg/kg day 1 and bendamustine 90 mg/m² day 1–2 Q3W for up to 6 cycles| ORR 78% (CR 43%, PR 35%) Medial PFS and median OS not reached                                   |
| Moskowitz et al. 2015 (AETHERA) [21] | 3 | 329| Consolidation after ASCT         | Bv 1.8 mg/kg vs placebo Q3W for 16 cycles                                | Bv (n = 165) vs placebo (n = 164): Medial PFS 42.9 vs 24.1 months (HR = 0.57, P = 0.0013)          |
| Chen et al. 2015 [22, 23]     | 2     | 37 | Relapsed after or refractory to frontline therapy | Bv 1.8 mg/kg Q3W for 4 cycles                                           | ORR 68% (CR 35%, PR 32%) 18 patients directly proceeded to ASCT; 18 patients received additional salvage chemotherapy and 15 proceeded to ASCT 18-month post-transplant PFS rate 73% |
| Moskowitz et al. 2015 [24]    | 2     | 45 | Relapsed after or refractory to frontline therapy | Bv 1.2 mg/kg days 1, 8, 15 Q4W for 2 cycles                              | 12 (27%) were PET negative and proceeded to ASCT; 32 received additional salvage chemotherapy and proceeded to ASCT 2-year EFS rate 80%, 2-year OS rate 95% |
| Cassaday et al. 2017 [25]     | 1/2   | 24 | Relapsed after or refractory to frontline therapy | Bv 1.2 or 1.5 mg/kg days 1, 8 Q3W in combination with ICE for 2 cycles   | 20 (87%) of 23 evaluable patients achieved PET CR 19 had undergone ASCT                              |
| Garcia-Sanz et al. 2016 [26]  | 2     | 66 | Relapsed after or refractory to frontline therapy | Bv 1.8 mg/kg Q3W in combination with ESHAP for 3 cycles                  | Pre-ASCT ORR 96% (CR 70%, PR 26%) 61 had undergone an ASCT Projected 1-year post-transplant PFS rate 87%, OS rate 90% |
| LaCasce et al. 2015 [27]      | 1/2   | 53 | Relapsed after or refractory to frontline therapy | Bv 1.8 mg/kg Q3W plus bendamustine 90 mg/m² days 1–2 Q3W for up to 6 cycles | ORR 93% (CR 74%, PR 19%) 37 had undergone ASCT Estimated 12-month PFS rate 80%                      |
| Younes et al. 2013 [29, 30]   | 1     | 51 | Newly diagnosed stage IIA bulky disease or stage IIB-IV | Bv 0.6, 0.9, or 1.2 mg/kg Q2W in combination with ABVD or AVD for up to 6 cycles (28-day) | Bv+ABVD arm (n = 25, dose escalation): CR 95% 5-year FFS rate 79%, OS rate 92% Bv+AVD arm (n = 26, 1.2 mg/kg only): CR 96% 5-year FFS rate 92%, OS rate 100% |
| Connors et al. 2018 (ECHELON-I) [31] | 3 | 1334| Untreated stage III or IV         | Bv 1.2 mg/kg Q2W in combination with AVD vs ABVD, for up to 6 cycles (28-day) | Bv+AVD vs ABVD: ORR 86 vs 83% CR 73 vs 70% 2-year modified PFS rate 82.1 vs 77.2% (HR = 0.77, P = 0.03) |
| Abramson et al. 2015 [33]     | 2     | 34 | Newly diagnosed non-bulky stage I-II | Bv 1.2 mg/kg Q2W for 1 cycle (28-day), followed by Bv+AVD for 4–6 cycles (28-day) | After first cycle of Bv: CR 53% After 2 cycles of Bv+AVD: CR 97% At the end of treatment: CR 88% PFS rate 90% and OS rate 97% (median follow-up 14 months) |
| Kumar et al. 2016 [34]        | 2     | 30 | Newly diagnosed stage I-II with unfavorable risk factors | Bv 1.2 mg/kg Q2W in combination with AVD for 4 cycles (28-day), followed by 30 Gy ISRT if PET negative | After 2 cycles: 90% PET negative After 4 cycles: 93% PET negative 1-year PFS rate 93.3% |
Table 1: Major clinical trials on brentuximab vedotin for treatment of Hodgkin lymphoma (Continued)

| Study                          | Phase | N  | Setting                          | Treatment                                                                 | Efficacy results                                                                 |
|-------------------------------|-------|----|----------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Evens et al. 2017 [37]        | 2     | 48 | Newly diagnosed stage IIIb−IV, age ≥ 60 years | Bv 1.8 mg/kg Q3W for 2 cycles, followed by AVD for 6 cycles, followed by 4 more cycles of Bv if responded | For evaluable patients (n = 41) After 2 cycles of Bv: ORR 87% (CR 30%) After completion of AVD: ORR 95% (CR 90%) At end of therapy: ORR 95% (CR 93%) 2-year PFS rate 90% |
| Park et al. 2016 [38, 39]     | 2     | 41 | Untreated limited stage non-bulky  | ABVD for 2–6 cycles, followed by Bv 1.8 mg/kg Q3W for 6 cycles            | After 2 cycles of ABVD: 72% PET negative After completion of Bv: 90% PET negative Estimated 2-year PFS rate 92%, OS rate 97% |
| Federico et al. 2016 [40]     | 2     | 12 | Untreated stages IA, IIA, and IIIA | Bv 1.8 mg/kg for 2 cycles, followed by ABVD for 3 or 6 cycles, and radiation therapy if indicated | After 2 cycles of Bv: ORR 92% (CR 83%, PR 8%) At the end of therapy: ORR 100% (CR 92%, PR 8%) 1-year PFS rate 92% |
| Eichenauer et al. 2017 [41]   | 2     | 104| Newly diagnosed advanced stage   | Bv 1.2 mg/kg plus ECAPP or ECADD for 6 cycles (21-day)                    | Bv+ECAPP arm (49 evaluable): CR 86%, 18-month PFS rate 95% Bv+ECADD arm (52 evaluable): CR 88%, 18-month PFS rate 89% |
| Friedberg et al. 2017 [42]    | 2     | 42 | Treat-naïve, age ≥ 60 years, ineligible for or declined standard frontline chemotherapies | Bv 1.8 mg/kg plus dacarbazine 375 mg/m² Q3W for 12 cycles followed by Bv 1.8 mg/kg day 1 plus bendamustine 90 mg/m² days 1–2 Q3W for 6 cycles followed by Bv 1.8 mg/kg for 10 cycles or more | Bv+dacarbazine arm (21 evaluable): ORR 100% (CR 62%, PR 38%) Median PFS 17.9 months Bv + bendamustine arm (20 evaluable): ORR 100% (CR 88%, PR 12%) Median PFS not reached |
| Forero-Torres et al. 2015 [44]| 2     | 27 | Treat-naïve, age ≥ 60 years, ineligible for or declined conventional combination treatment | Bv 1.8 mg/kg Q3W for up to 16 cycles; additional cycles allowed in those with clinical benefit | ORR 92% (CR 73%, PR 19%) Median PFS 10.5 months |
| Gibbs et al. 2017 (BREVITY) [45] | 2     | 38 | Untreated, unfit for standard treatment | Bv 1.8 mg/kg Q3W for up to 16 cycles                                    | For evaluable patients (n = 31): CMR after 4 cycles 26% ORR 84% Median PFS 7.4 months |

N patient number; Bv brentuximab vedotin; Q3W every 3 weeks; Q4W every 4 weeks; MTD maximum tolerated dose; ABVD adriamycin, bleomycin, vinblastine, dacarbazine; AVD adriamycin, vinblastine, dacarbazine; ECADD etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; ECAPP etoposide, cyclophosphamide, doxorubicin, procarbazine, and prednisone; ESHAP etoposide, Solu-Medrol, high-dose cytarabine, cisplatin; ICE ifosfamide, carboplatin, etoposide; ISRT involved-site radiotherapy; ASCT autologous stem cell transplantation; ORR objective response rate; CR complete response; PR partial response; CMR complete metabolic response; PFS progression-free survival; FFS failure-free survival; OS overall survival; HR hazard ratio

(17%) [11]. In another phase 1 dose-escalation study, brentuximab vedotin was given on days 1, 8, and 15 of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. The MTD was 1.2 mg/kg. In 35 HL patients, the ORR was 54%, with 10 CR and 9 PR. For the 12 patients who were treated at the MTD, the ORR was 58%, with 3 CR (25%) and 4 PR (33%) [12]. In a Japanese phase 1/2 study, five CR (56%) and one PR (11%) were observed in nine HL patients in the phase 2 portion (1.8 mg/kg every 3 weeks), with an ORR of 67% [13].

In the pivotal phase 2 trial of brentuximab vedotin in relapsed or refractory HL after ASCT, 102 patients were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of 16 cycles. The most common treatment-related adverse events (AEs) were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. The ORR was 75%, with 34% CR and 40% PR. The median duration of response (DOR) in those with a CR was 20.5 months [14]. At 3-year follow-up, median progression-free survival (PFS) and median overall survival (OS) was 9.3 and 40.5 months, respectively [15]. With longer follow-up, the 5-year PFS and OS rates were 22 and 41%, respectively. In patients who achieved CR, the 5-year PFS and OS rates were 52 and 64%, respectively, and the median PFS and OS were not reached suggesting that some patients may be cured [16]. This pivotal trial met its primary endpoint (ORR) and was the basis for FDA approval of brentuximab vedotin in August 2011 for patients with HL after failure of ASCT or at least two prior multi-agent chemotherapy regimens if not eligible for ASCT. This was the first FDA-approved treatment for HL since 1977.

Brentuximab vedotin also demonstrated activity in relapsed or refractory HL after allogeneic stem cell transplantation (Allo-SCT). In a multicenter study, 25
patients received 1.2 or 1.8 mg/kg of brentuximab vedotin every 3 weeks. The ORR was 50%, with 38% CR, and the median PFS was 7.8 months [17].

In patients with relapsed or refractory HL previously treated with brentuximab vedotin, retreatment may be an option. This is supported by a phase 2 study in HL and ALCL patients with disease progression or relapse following discontinuation of brentuximab vedotin after achieving CR or PR (on a previous clinical trial). In 20 HL patients evaluable for efficacy, the ORR was 60%, with 30% CR and 30% PR. The median DOR was 9.2 months, and the median PFS was 9.9 months. AE profile during retreatment was similar to that observed in the pivotal trials, with the exception of higher rates of peripheral neuropathy due to the cumulative effect [18].

Brentuximab vedotin in combination with bendamustine was tested in relapsed or refractory HL. In a phase 1/2 study, patients (predominantly HL) were treated with brentuximab vedotin on day 1 and bendamustine on days 1 and 2 of every 3-week cycle for up to 6 cycles. Forty-two patients had received an ASCT and three patients an Allo-SCT prior to enrollment. Eleven patients were previously exposed to brentuximab vedotin. In the phase 1 portion of the study, the MTD was not reached. The highest dose (brentuximab vedotin 1.8 mg/kg and bendamustine 90 mg/m²) was chosen for phase 2. The ORR in phase 1 (n = 28, 27 HL) was 61%, with 18% CR and 43% PR. The ORR in phase 2 (n = 37, all HL) was 78%, with 43% CR and 35% PR. The median PFS and OS were not reached in phase 2 [19]. Although the ORR was similar, the CR rate appeared higher compared to that observed in the pivotal trials, with the exception of higher rates of peripheral neuropathy due to the cumulative effect [18].

Brentuximab vedotin consolidation therapy following ASCT in cHL patients with a high risk of relapse.

**Salvage therapy after frontline therapy**

The role of brentuximab vedotin in salvage therapy for patients with refractory or relapsed disease after frontline therapy was evaluated by a few studies. In a phase 2 study led by the City of Hope investigators, cHL patients were treated with brentuximab vedotin (1.8 mg/kg every 3 weeks) for a total of 4 cycles and proceeded to ASCT if eligible with or without additional salvage therapy based on remission status. The ORR in 37 treated patients was 68%, with 35% CR and 32% PR [22]. Eighteen patients (13 CR, 4 PR, 1 stable disease (SD; received additional radiation therapy) proceeded to ASCT without additional salvage chemotherapy. Eighteen patients received additional salvage therapy, with 11 achieving CR and 4 achieving PR and proceeded to ASCT [22, 23]. After a median follow-up of 17.6 months, the 18-month post-transplant PFS rate was 73% [23]. In another phase 2 study conducted at the Memorial Sloan Kettering Cancer Center, 45 patients were treated with brentuximab vedotin (1.2 mg/kg on days 1, 8, and 15 of every 28-day cycle) for 2 cycles. Twelve patients (27%) achieved positron emission tomography (PET) negativity and directly proceeded to ASCT. Thirty-two of the 33 PET-positive patients went on to receive 2 cycles of augmented ICE (ifosfamide, carboplatin, etoposide). Twenty-two of them achieved PET negativity and proceeded to ASCT. The other 10 patients all went on to ASCT eventually (1 after 1 additional cycle of augmented ICE, 6 after involved-field radiation therapy (IFRT), and 3 without additional therapy). After a median follow-up of 20.1 months, the 2-year event-free survival (EFS) was 80% and OS was 95% [24]. These results demonstrated that brentuximab vedotin is an active first-line salvage therapy, producing 27–35% CR as a single agent. Another 30–49% of patients could achieve a CR with additional salvage therapy. The majority of patients could proceed to ASCT.

Brentuximab vedotin in combination with conventional salvage chemotherapy can potentially improve outcome with salvage therapy and make more cHL patients eligible for ASCT. The brentuximab vedotin and ICE combination produced a high PET CR rate as first-line salvage therapy in an ongoing phase 1/2 trial at the University of Washington. Brentuximab vedotin (1.2 or 1.5 mg/kg in phase 1 dose escalation, and 1.5 mg/kg in phase 2) was given on days 1 and 8 every 3 weeks in phase 1/2 for 4-6 cycles.
combination with ICE for 2 cycles. Therapy was well tolerated. At the time of report at ASH 2017, 20 (87%) of 23 evaluable cHL patients achieved PET CR and 19 had undergone an ASCT [25]. The combination of brentuximab vedotin with ESHAP (etoposide, Solu-Medrol, high-dose cytarabine, cisplatin) is also highly effective as a first-line salvage therapy. In a GELTAMO phase 2 trial, patients were treated with brentuximab vedotin (1.8 mg/kg every 3 weeks) and ESHAP for 3 cycles. At the time of report at ASH 2016, 66 cHL patients completed pre-transplant treatment. The addition of brentuximab vedotin did not result in a higher toxicity. The ORR was 96%, with 70% CR and 26% PR. Sixty-one patients had undergone ASCT. In 47 patients with available data, 37 (80%) were in CR and 3 (7%) were in PR after transplant. With a mean follow-up of 11 months, the projected 1-year post-transplant PFS rate was 87% and OS rate was 90% [26].

Brentuximab vedotin in combination with bendamustine was also very effective for first-line salvage therapy. In a phase 1/2 study, brentuximab vedotin (1.8 mg/kg every 3 weeks) and bendamustine (90 mg/m² on days 1 and 2 every 3 weeks) for up to 6 cycles resulted in a CR rate of 74% (39/53) and an ORR of 93% (49/53) [27]. The response rates were higher compared to those when the combination was used in multiply relapsed or refractory patients [19]. Thirty-seven patients went on to ASCT. The estimated 12-month PFS was 80% for both the transplanted population and the overall population [27]. In a phase 2 trial by the Children’s Oncology Group, pediatric and young adult patients (≤30 years) were treated with brentuximab vedotin (1.8 mg/kg every 3 weeks) and gemcitabine (1000 mg/m² on days 1 and 8 every 3 weeks) for up to 4 cycles, and the CR rate was 58% (23/40) and the ORR was 73% (29/40) [28]. While the combination of brentuximab vedotin and gemcitabine appeared less effective in this setting, one should note that the populations in the studies were very different.

**Frontline therapy**

Incorporation of brentuximab vedotin in frontline therapy of HL is a current research focus, in the hope of improving cure rates. In the initial phase 1 dose-escalation study, cHL patients with stage IIA bulky disease or stage IIB-IV disease were treated with brentuximab vedotin plus ABVD or adriamycin, vinblastine, dacarbazine (AVD) for up to 6 cycles. The MTD of brentuximab vedotin in this setting was not exceeded at 1.2 mg/kg. The CR rate was 95% (21/22) in the ABVD arm and 96% (24/25) in the AVD arm [29]. With long-term follow-up, the 5-year failure-free survival (FFS) and OS rates were 79 and 92% in the brentuximab vedotin plus ABVD arm and 92 and 100% in the brentuximab vedotin plus AVD arm, respectively [30]. Importantly, the brentuximab vedotin plus ABVD combination produced a high rate of pulmonary toxicity (44%) [29], suggesting intolerance and infeasibility for further development. Following this study, the large phase 3 ECHELON-1 study compared brentuximab vedotin plus AVD (n = 664) with ABVD (n = 670) in previously untreated stage III or IV cHL. Brentuximab vedotin (1.2 mg/kg) plus AVD or ABVD were given on days 1 and 15 every 4 weeks for up to 6 cycles. The primary end point was modified PFS, defined as time to disease progression, death, or modified progression (evidence of non-complete response after completion of frontline therapy, followed by subsequent anticancer therapy). The brentuximab vedotin plus AVD regimen resulted in more myelosuppression and neurotoxicity but substantially less pulmonary toxicity and appeared more effective for frontline treatment for advanced stage cHL. The CR and ORR rates were 73 and 86% in the brentuximab vedotin plus AVD group and 70 and 83% in the ABVD group. After a median follow-up of 24.9 months, the 2-year modified PFS rate was significantly higher in the brentuximab vedotin plus AVD group (82.1 vs 77.2%, HR = 0.77, P = 0.03) [31].

Based on these data, brentuximab vedotin was approved by FDA in March 2018 to treat adult patients with previously untreated stage III or IV cHL in combination with chemotherapy. Brentuximab vedotin plus AVD will potentially challenge the ABVD regimen as the new standard therapy for advanced stage cHL patients. However, the need for growth factor support and the high cost associated with this regimen must be considered. In addition, since the RATHL trial showed equivalent outcomes for cHL patients treated with 6 cycles of ABVD versus 2 cycles of ABVD followed by 4 cycles of AVD in the setting of a negative interim PET [32], the advantage of reduced pulmonary toxicity of brentuximab vedotin plus AVD compared to ABVD for 6 cycles in the ECHELON-1 trial will likely be less appealing.

In early-stage HL, brentuximab vedotin in combination with AVD have been studied in a few trials, and it is highly effective. In a phase 2 study, cHL patients with non-bulky stage I–II disease received a lead-in cycle of brentuximab vedotin (1.2 mg/kg, days 1 and 15), followed by brentuximab vedotin plus AVD for 4–6 cycles. After the monotherapy lead-in, 18 of 34 (53%) patients achieved CR. After 2 cycles of brentuximab vedotin plus AVD, 33 patients (97%) were in CR (1 off study due to toxicity). At the end of treatment, 30 (88%) patients were in CR (2 had progressive disease (PD) and 2 were off study due to toxicity). After a median follow-up of 14 months, PFS and OS rates were 90 and 97%, respectively [33]. In a phase 2 study of stage I–II cHL with unfavorable risk factors, brentuximab vedotin (1.2 mg/kg) and AVD were given for 4 cycles (days 1 and 15 of the 28-
day cycle), followed by 30 Gy involved-site radiation therapy (ISRT) if PET was negative. After 2 and 4 cycles of therapy, 90% (26/29) and 93% (27/29) of patients were PET negative, respectively. All 25 patients who completed chemotherapy and ISRT achieved CR. After a median follow-up of 18.8 months, the 1-year PFS rate by intention to treat (ITT) was 93.3% [34]. In the second cohort of this study, ISRT was reduced to 20 Gy. The response rates were identical, with 90% (26/29) and 93% (27/29) of patients being PET negative after 2 and 4 cycles of therapy, respectively. All 28 patients who completed all therapies achieved CR [35]. Finally, an ongoing randomized phase 2 trial by the Lysa-FIL–EORTC intergroup is comparing 4 cycles of brentuximab vedotin plus AVD with ABVD followed by 30 Gy of involved-node radiation therapy (INRT) in stage I–II HL with unfavorable risk factors. At the time of report at ASH 2017, 93 of 113 patients (82.3%) in the brentuximab vedotin plus AVD arm and 43 of 57 patients (75.4%) in the ABVD arm were PET negative after 2 cycles of treatment [36].

For older patients with advanced stage disease, a sequential brentuximab vedotin and AVD regimen was investigated in a multicenter phase 2 study. Patients ≥60 years with stage IIB–IV cHL were treated with two lead-in cycles of brentuximab vedotin (1.8 mg/kg every 3 weeks) followed by 6 cycles of AVD. Responding patients went on to receive four more cycles of consolidative brentuximab vedotin. In 41 evaluable patients, the CR and ORR rates after the lead-in were 30 and 87%, respectively. After completion of AVD, the CR and ORR rates were 90 and 95%, respectively. One patient has improved response to CR after brentuximab vedotin consolidation, resulting in a final CR rate of 93%. After a medium follow-up of 24 months, the 2-year PFS rate was 90% [37].

Given the excessive pulmonary toxicity, combination of brentuximab vedotin and ABVD is not feasible for further investigation [29]. However, sequential therapy has been investigated in a couple of studies. In a multicenter phase 2 study, patients with limited stage non-bulky HL were treated with ABVD for 2–6 cycles, followed by brentuximab vedotin (1.8 mg/kg every 3 weeks) for 6 cycles. After 2 cycles of ABVD, 72% of the 40 evaluable patients were PET negative. After completion of brentuximab vedotin consolidation, 90% of patients were PET negative. With a median follow-up of 12 months, the estimated 1-year PFS and OS rates were 91 and 96%, respectively [38]. The updated results showed that 37 of 39 evaluable patients were PET negative after the completion of therapy. With a median follow-up of 22 months, the estimated 2-year PFS and OS rates were 92 and 97%, respectively [39]. In another phase 2 study, patients with stage IA, IIA, and IIIA HL were treated with brentuximab vedotin (1.8 mg/kg) for 2 cycles followed by ABVD for 3 or 6 cycles, with or without radiation therapy. After 2 cycles of brentuximab vedotin, 10 of 12 patients (83%) achieved CR and 1 patient (8%) achieved PR. At the end of therapy, the ORR was 100%, with 92% CR and 8% PR. The 1-year PFS rate was 92% [40].

The German Hodgkin lymphoma Study Group incorporated brentuximab vedotin into modified escalated BEACOPP as frontline therapy for advanced stage cHL. Patients were randomized to 6 cycles of either brentuximab vedotin plus ECAPP (etoposide, cyclophosphamide, doxorubicin, procarbazine, and prednisone) or brentuximab vedotin plus ECADD (etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone). After completion of chemotherapy, the CR rate was 86% (42/49) in the BrECAPP (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, procarbazine, and prednisone) arm and 88% (46/52) in the BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) arm. Consolidation radiotherapy was given to seven patients in the BrECAPP arm and six patients in the BrECADD arm (Deauville score of 4 or above). After completion of all therapies, the CR rate increased to 94% (46/49) in the BrECAPP arm but remained at 88% (46/52) in the BrECADD arm. The 18-month PFS rate was 95% in the BrECAPP arm and 89% in the BrECADD arm [41]. The brentuximab vedotin plus ECADD regimen was associated with a more favorable toxicity profile and is currently being compared to the standard escalated BEACOPP in the phase 3 HD21 study.

Older HL patients tend to do poorly with conventional frontline chemotherapy regimens due to comorbidities and treatment-related toxicities. Less intensive combination regimens have been investigated in elderly patients with HL. In a multicenter phase 2 study, cHL patients ≥60 who were ineligible or declined standard frontline therapy such as ABVD or BEACOPP were treated with brentuximab vedotin (1.8 mg/kg) plus dacarbazine (up to 12 cycles) or bendamustine (up to 6 cycles). Additional cycles of brentuximab vedotin were allowed to complete a total of 16 cycles or more. The ORR was 100% in both arms. The CR rate was 62% in the dacarbazine arm (n = 22) and 88% in the bendamustine arm (n = 20). Although brentuximab vedotin plus bendamustine appeared more active, this regimen also caused more serious AEs (65 vs 18%) [42]. Of note, half of the patients in this study had at least three comorbidities or were impaired in at least one aspect that significantly interfered with their quality of life. In these patients, brentuximab vedotin plus bendamustine should be used with caution and many elderly patients may not be eligible for this therapy at these doses. In the phase 1/2 HALO study in France and Italy, a lower dose of
brentuximab vedotin (1.2 mg/kg) plus bendamustine (up to 6 cycles) was used for elderly patients with stage IIB–IVB cHL disease. Twelve patients were treated in phase 1, and the treatment-related toxicities were largely hematological and manageable. The study is currently in the phase 2 portion. At the time of report at ASH 2016, nine patients had PET scans available for efficacy evaluation. All patients achieved complete metabolic response (CMR), seven after 2 cycles and two after 4 cycles [43]. Therefore, a lower dose of brentuximab vedotin in combination with bendamustine can be a promising frontline treatment option for elderly patients.

Single-agent brentuximab vedotin for frontline therapy in elderly HL patients has also been investigated. A multicenter phase 2 clinical trial evaluated the efficacy of brentuximab vedotin in cHL patients 60 years or older. Twenty-seven patients were treated with brentuximab vedotin (1.8 mg/kg every 3 weeks) for up to 16 cycles. Patients with clinical benefit could continue treatment beyond 16 cycles until disease progression, unacceptable toxicity, or study closure. The ORR was 92%, with 73% CR. The median PFS was relatively short at 10.5 months, and the median OS was not reached [44]. The BREVITY trial in UK is another study that evaluated single-agent brentuximab vedotin in newly diagnosed HL patients unsuitable for standard chemotherapy. Thirty-eight patients were enrolled and treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for up to 16 cycles. At the time of report at the International Conference on Malignant Lymphoma (ICML) in 2017, 31 patients were evaluable for response. CMR rate was 26% after 4 cycles of therapy. The ORR was 84%. The median PFS was 7.4 months [45]. In elderly or unfit patients, brentuximab vedotin produced a high ORR, but the PFS was short. Management of this patient population therefore remains challenging.

**Bispecific antibodies**

Immunotherapy with bispecific mAbs that bridge tumor cells and immune effector cells has achieved some success in both solid tumors and hematological malignancies. Effective therapies include catumaxomab for EpCam-positive gastric and ovarian cancer and blinatumomab for CD19-positive acute lymphoblastic leukemia (ALL). In HL, this strategy has been under development. In the 1990s, Hartmann and colleagues developed a murine bispecific Ab, HRS-3/A9, that targets CD30 and CD16 (Fcγ-receptor III on NK cells and mononuclear phagocytes). In the first phase 1/2 trial, they treated 15 patients with relapsed or refractory HL with HRS-3/A9 (four infusions every 3–4 days) and observed 1 CR (lasting 6 months), 1 PR (lasting 3 months), and 3 MR (lasting 1 to 15 months). The treatment was well tolerated and the MTD was not reached at 64 mg/m². However, eight patients developed human anti-mouse immunoglobulin antibodies, and retreatment was prevented by allergic reactions in all five attempted cases [46]. In a subsequent trial, they treated 16 patients with 100 mg HRS-3/A9 (25 mg daily every other day or continuous infusion over 4 days). In cases with an objective response, retreatment was attempted after 4 weeks, and in cases with stable disease, a second course was given after pre-stimulation with IL-2 followed by GM-CSF. Overall, one CR and three PR lasting 5–9 months were observed. The one CR and one of the three PRs were achieved after the second course of HRS-3/A9 with IL-2 pretreatment [47]. Although a second course treatment was uneventful in all eight attempted cases, a third treatment course was attempted in only one patient with considerable urticaria developed, suggesting that repeated treatment is unlikely to be feasible likely due to development of anti-mouse antibodies.

A chimeric bispecific mAb AFM13 targeting CD30 and CD16A was developed recently and appears promising. In a German phase 1 study, 28 patients with heavily pretreated relapsed or refractory cHL received AFM13 at escalating doses (0.01 to 7 mg/kg, weekly for four doses). One more course of treatment could be given if patients achieve SD or better. Therapy was well tolerated, and the MTD was not reached. In 26 evaluable patients, there were 3 PR and 13 SDs. All three patients with PR received a dose of 1.5 mg/kg or higher [48]. The safety profile and efficacy results were encouraging, and the investigators suggested further development with higher doses and prolonged treatment.

Another bispecific mAb H22xKi-4 was developed in the late 1990s, targeting CD30 and CD64 (Fcγ-receptor I on macrophages and monocytes). In a phase 1 study, 10 patients with refractory HL were treated with escalating doses (1–20 mg/m²/day every other day for four doses). The therapy was well tolerated. Overall, there were one CR, three PR, and four SDs, indicating encouraging efficacy [49]. However, no further development of CD30/CD64-targeting was reported.

**CD30 CAR-T cells**

T cells engineered to express chimeric antigen receptors (CAR) targeting CD19 or CD20 have shown impressive activity in a number of hematologic malignancies such as ALL and B cell lymphoma. CD30 is an attractive target for CAR-T cell-based immunotherapy in HL. Two reports have been published recently using CD30 CAR-T cells. A phase 1 trial conducted in China enrolled 18 patients with relapsed or refractory HL. Patients received an infusion with a mean of $1.56 \times 10^7$ CAR-T cells/kg. The therapy was well tolerated, with grade ≥ 3 toxicities occurring in only 2 of 18 patients (liver function test abnormality and left ventricular systolic dysfunction,
respectively. Seven patients (39%) achieved PR, and six achieved SD, suggesting promising activity of CD30 CAR-T cells in this heavily pretreated population [50]. Most recently, Baylor investigators reported a phase 1 study of CD30 CAR-T cells in seven HL and two ALC patients. Patients received one to four infusions of 0.2–2 x 10⁸ CD30 CAR-T cells/m² without conditioning and tolerated the therapy well. Four HL patients received 2 x 10⁸ CD30 CAR-T cells/m². One patient achieved and remained in CR after 2 years following CAR-T cell infusion. Another patient achieved and remained in CR after 2.5 years after two infusions [51]. The durable CR is particularly encouraging, and tumor debulking and lymphodepletion before CD30 CAR-T cell infusion may further enhance their clinical activity.

**PD-1-targeted immunotherapy**

It has long been recognized that H RS cells are surrounded by an extensive background of inflammatory and immune cells. However, there is little evidence of an effective antitumor immune response. In fact, the H RS cells produce molecules that inhibit T cell-mediated immune responses. Importantly, PD-L1 expressed on H RS cells engages PD-1 expressed on T cells, induces immune checkpoint inhibition, and causes T cell exhaustion. Shipp and colleagues demonstrated that chromosome 9p24.1 amplification is a recurrent genetic abnormality in the nodular sclerosis type of cHL, leading to overexpression of genes contained in this region including PD-L1, PD-L2, and JAK2. The enhanced JAK-STAT signaling may further increase PD-L1 expression [3]. This inherent genetic abnormality suggests that HL may have genetically determined vulnerability to immunotherapy with PD-1 blockade. Two PD-1 mAbs, nivolumab and pembrolizumab, have demonstrated high activities in the treatment of HL (Table 2).

**Nivolumab**

**Therapy for relapsed and refractory disease**

Nivolumab is an IgG4 fully human anti-PD-1 mAb that is efficacious in treating a number of solid tumors. Its activity in HL was first demonstrated in a phase 1 study (CheckMate 039) led by Ansell and colleagues. In the expansion cohort of this study, patients with relapsed or refractory cHL were treated with nivolumab (3 mg/kg) every 2 weeks until disease progression, excessive toxicity, CR, or a maximum of 2 years. At the time of report, 23 patients were enrolled, 78% had received ASCT and 78% had received prior brentuximab vedotin. The ORR was 87%, with 17% CR and 70% PR, and the PFS rate at 24 weeks was 86% [52]. Extended follow-up showed that 10 of the 20 objective responses were durable. In the remaining 10 responders, 5 proceeded to stem cell transplant (4 Allo-SCT and 1 ASCT), 1 discontinued due to toxicity but did not progress at 4-month follow-up, and the other 4 progressed. These data suggest that nivolumab is highly effective in treating multiply relapsed cHL patients, providing durable remissions and/or allowing patients to proceed to a stem cell transplant [53]. Following the CheckMate 039 study, the phase 2 CheckMate 205 study was designed to further evaluate the efficacy of nivolumab in cHL after ASCT. Cohort B of this study was for patients who failed both ASCT and subsequent brentuximab vedotin. Eighty patients were treated with nivolumab (3 mg/kg) every 2 weeks until disease progression, death, or unacceptable toxicity. The ORR was 66%, with 9% CR and 58% PR [54]. According to updated data presented at ASH 2016 based on longer follow-up, the median PFS was 14.8 months. The 12-month PFS rate was 54.6%, and the 12-month OS rate was 94.9%. These data suggest that nivolumab monotherapy can produce durable remissions in heavily pretreated cHL patients after failure of ASCT and brentuximab vedotin [55]. Data from CheckMate 039 and CheckMate 205 were the basis of the FDA approval in May 2016 of nivolumab for cHL that has relapsed or progressed after ASCT and posttransplantation brentuximab vedotin. This was the first approval of checkpoint inhibitors in hematological malignancies.

The activity of nivolumab in treating relapsed and refractory disease is further supported by additional studies. The CheckMate 205 trial also included cHL patients who were brentuximab vedotin naive (cohort A, n = 63) and who received brentuximab vedotin before or after ASCT (cohort C, n = 100). Patients received the same treatment as those in cohort B. Results after an extended follow-up showed that the ORR in cohorts A, B, and C were 65, 68, and 73%, respectively. The CR rates were 29, 13, and 12%, respectively, and the median DOR was 20.3, 15.9, and 14.5 months in cohorts A–C, respectively. The median PFS in the three cohorts were 18.3, 14.7, and 11.9 months, respectively [56]. These data demonstrated high response rates and durable response to nivolumab regardless of brentuximab vedotin exposure. A Japanese phase 2 study evaluated the efficacy of nivolumab in patients with relapsed or refractory cHL who failed or were ineligible for brentuximab vedotin. Nivolumab (3 mg/kg) was administered every 2 weeks. In 16 patients evaluable for efficacy, the ORR was 81%, with 25% CR and 56% PR. The 6-month PFS and OS rates were 60 and 100%, respectively [57].

A French retrospective study assessed the safety and efficacy of nivolumab in HL patients who relapsed after Allo-SCT. Six (30%) of the 20 treated patients developed graft-versus-host disease (GVHD), all of which had prior history of acute GVHD. Two patients responded to steroids; two patients required alternative immunosuppressive therapy, and two patients died of GVHD. After a
median follow-up of 1 year, the 1-year PFS and OS rates were 58.2 and 78.7%, respectively. Thirteen patients were still in response [58]. These data suggest that nivolumab is an effective therapy for this population, although the risk of GVHD is significant.

**Frontline therapy**

Given the efficacy of nivolumab for relapsed and refractory HL, studies are now ongoing investigating its role in frontline therapy of HL. Cohort D of the CheckMate 205 study enrolled patients with newly diagnosed advanced stage cHL (stage II with B symptoms and extra nodal or bulky disease, III and IV). Patients were treated with nivolumab (240 mg biweekly) for four doses, followed by nivolumab plus AVD for 6 cycles. At the time of report at ASH 2017, 51 patients were enrolled, with 49 completed nivolumab monotherapy and 44 completed nivolumab plus AVD. At the end of therapy, the ORR per investigator review for the ITT population was 84%, with 80% CR and 4% PR. The modified PFS rate at 9 months was 94% [59]. The ORR and CR rates were at least similar to those for the brentuximab vedotin plus AVD and ABVD arms in the ECHELON-1 study, suggesting that nivolumab plus AVD is another promising frontline therapy for cHL, although longer follow-up from CheckMate 205 as well as larger randomized studies are needed for validation.

**Combination therapy**

Combination immunotherapy with nivolumab and ipilimumab, another immune checkpoint inhibitor blocking

---

**Table 2 Major clinical trials on nivolumab and pembrolizumab for treatment of Hodgkin lymphoma**

| Study            | Trial name                  | Phase | N  | Setting                                                                 | Treatment                                                                 | Efficacy results                                                                 |
|------------------|-----------------------------|-------|----|-------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Ansell et al.    | CheckMate 039               | 1     | 23 | Relapsed or refractory                                                  | Nivolumab 3 mg/kg Q2W for up to 2 years                                   | ORR 87% (CR 17%, PR 70%) PFS rate at 24 weeks 86%                           |
| Younes et al.    | CheckMate 205               | 2     | 80 | Relapsed or refractory after ASCT and brentuximab vedotin              | Nivolumab 3 mg/kg Q2W                                                    | ORR 68% (CR 13%, PR 55%) 12-month PFS rate 54.6%, OS rate 94.9% Median PFS 14.7 months |
| Armand et al.    | CheckMate 205               | 2     | 63 | Cohort A: relapsed or refractory, brentuximab vedotin naïve            | Nivolumab 3 mg/kg Q2W                                                    | Cohort A: ORR 65% (CR 29%) Median DOR 20.3 months                          |
|                  | (cohorts A and C)           |       | 100| Cohort C: relapsed or refractory after brentuximab vedotin             |                                                                            | Cohort C: ORR 73% (CR 12%) Median DOR 14.5 months Medial PFS 11.9 months |
| Herbaux et al.   |                              | 20    |    | Relapsed after Allo-SCT                                                 | Nivolumab 3 mg/kg Q2W                                                    | ORR 95% (CR 42%, PR 52%) 1-year PFS rate 58.2%, OS rate 78.7%               |
| Ramchandren et al.| CheckMate 205               | 2     | 51 | Newly diagnosed advanced stage                                          | Nivolumab 240 mg biweekly for 4 doses, followed by nivolumab plus AVD for 6 cycles | ORR 84% (CR 80%, PR 4%) Modified PFS rate at 9 months 94%                   |
| Ansell et al.    | CheckMate 039               | 1     | 31 | Relapsed or refractory                                                  | Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for 4 cycles, followed by nivolumab 3 mg/kg Q2W for up to 2 years | ORR 74% (CR 19%, PR 55%)                                                    |
| Herrera et al.   |                              | 1/2   | 62 | Relapsed or refractory after or refractory to frontline therapy        | Nivolumab 3 mg/kg plus brentuximab vedotin 1.8 mg/kg Q3W for up to 4 cycles | ORR 83% (CR 62%)                                                          |
| Armand et al.    | KEYNOTE-013                 | 1b    | 31 | Relapsed or refractory after brentuximab vedotin                       | Pembrolizumab 10 mg/kg Q2W for up to 2 years                              | ORR 65% (CR 16%, PR 48%) median PFS 11.4 months 6-month PFS rate 66%, OS rate 100% 12-month PFS rate 48%, OS rate 87% |
| Chen et al.      | KEYNOTE-087                 | 2     | 210| Relapsed or refractory after ASCT and/or brentuximab vedotin          | Pembrolizumab 200 mg Q3W for up to 2 years                                | ORR 69.0% (CR 22.4%, PR 46.7%) 6-month PFS rate 72.4%, OS rate 99.5% 9-month PFS rate 63.4%, OS rate 97.5% |

N patient number, Q2W every 2 weeks, Q3W every 3 weeks, AVD adriamycin, vinblastine, dacarbazine, ASCT autologous stem cell transplantation, ORR objective response rate, CR complete response, PR partial response, PFS progression-free survival, OS overall survival
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has been shown to be superior to monotherapies in treating some solid tumors including melanoma. Arm 2 of the CheckMate 039 study evaluated the efficacy of nivolumab and ipilimumab in hematological malignancies. Patients were treated with nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 cycles, followed by nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. At the time of report at ASH 2016, 65 patients were treated, including 31 HL patients. The ORR in HL patients was 74%, with 19% CR and 55% PR [60]. The CR rate appeared similar to nivolumab monotherapy (17%) [52, 56]. The benefit of adding ipilimumab in this setting needs further study.

Given the efficacy of both nivolumab and brentuximab vedotin, the combination is currently being investigated in HL. The ECOG-ACRIN E4412 trial is studying the combination of brentuximab vedotin with nivolumab or ipilimumab or both in relapsed or refractory HL. Preliminary results from arm D (nivolumab 3 mg/kg plus brentuximab vedotin 1.2 mg/kg, n = 3), arm E (nivolumab 3 mg/kg plus brentuximab vedotin 1.8 mg/kg, n = 7), and arm F (expansion cohort, n = 9) were reported at ICML in 2017. In 17 patients evaluable for response, the ORR was 89% and the CR rate was 50% [61]. The high CR and ORR were encouraging, suggesting a deepening of response compared with either therapy alone. In another multicenter phase 1/2 study, cHL patients who relapsed or were refractory to frontline chemotherapy were treated with nivolumab (3 mg/kg) plus brentuximab vedotin (1.8 mg/kg) every 3 weeks for up to 4 cycles. Sixty-two patients were enrolled, and 58 completed 4 cycles of treatment. In 60 patients evaluable for efficacy, the ORR was 83%, and the CR rate was 62%. Seventeen patients received additional salvage therapy subsequent to study treatment (ICE for the majority). Fifty-four patients had undergone ASCT [62]. The high CR rate in this study suggests that this combination is a very promising salvage therapy after failure to frontline chemotherapy.

Pembrolizumab

Pembrolizumab is an IgG4 fully human anti-PD-1 mAb. Like nivolumab, it is efficacious in treating a variety of solid tumors and has also demonstrated a high activity in HL. KEYNOTE-013 was the initial phase 1b study that evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory cHL. Thirty-one patients were enrolled. All of them had prior exposure to brentuximab vedotin, and 71% had relapsed after ASCT. Pembrolizumab (10 mg/kg) was administered every 2 weeks for 2 years or until disease progression or unacceptable toxicity. The ORR was 65%, with 16% CR and 48% PR [63]. Updated efficacy data was reported at ASH 2016 with a median follow-up of 24.9 months. Per blinded independent central review, the median PFS was 11.4 months and the 6- and 12-month PFS rates were 66 and 48%, respectively. The 6- and 12-month OS rates were 100 and 87%, respectively [64].

Following KEYNOTE-013, the phase 2 KEYNOTE-087 trial was conducted to further evaluate the efficacy of pembrolizumab in relapsed or refractory cHL. A total of 210 cHL patients who had prior ASCT and/or brentuximab vedotin were included. Pembrolizumab (200 mg) was administered every 3 weeks for 2 years or until disease progression or intolerable toxicity. The ORR by central review was 69.0%, with 22.4% CR and 46.7% PR. The response rates were similar in pre-specified cohorts (progression after [1] ASCT and subsequent brentuximab vedotin, [2] salvage chemotherapy and brentuximab vedotin, ineligible for ASCT, or [3] ASCT without post-transplant brentuximab vedotin). At 6 months, the PFS rate was 72.4% and the OS rate was 99.5%. The 9-month PFS and OS rates were 63.4 and 97.5%, respectively [65]. Based on the results of this trial, the FDA-approved pembrolizumab in March 2017 for the treatment of patients with refractory cHL, or who have relapsed after three or more prior lines of therapy.

Avelumab

Avelumab is a fully human anti-PD-L1 mAb. Blocking the PD-1 checkpoint with avelumab has also been shown to be effective for the treatment of relapsed or refractory HL. In the phase 1 JAVELIN HOGKINS study, cHL patients who progressed after or were ineligible for stem cell transplant were treated with avelumab at five different dosing regimens (70 mg, 350 mg, 500 mg every 2 weeks (Q2W), 500 mg every 3 weeks (Q3W), or 10 mg/kg Q2W). Treatments were well tolerated. The ORR was 54.8% with two CRs (6.5%) and 15 PRs (48. 4%). Responses were observed in all dosing groups, with ORR ranging from 14.3 to 83.3% [66]. The ORR appeared similar to that observed with nivolumab and pembrolizumab, but further studies are certainly needed.

Conclusions

Classical HL has unique biology, and this provides opportunities for novel targeted therapies. Brentuximab vedotin targeting CD30 and nivolumab and pembrolizumab targeting PD-1 have demonstrated impressive single-agent activity in treating relapsed and refractory cHL and have received FDA approval for this indication. Ongoing clinical studies have been evaluating their roles in treating cHL at first relapse and at initial diagnosis and encouraging results have been demonstrated including those leading to the approval of brentuximab vedotin for untreated stage III–IV cHL patients in combination with chemotherapy. As these results impact the current
standards of care, the use of these agents in earlier lines of therapy may improve the overall outcome of patients with CHL. Improving the cure rates of frontline therapy by using combinations that incorporate novel agents will not only improve disease outcome generally, but will also spare patients from long-term toxicity from conventional chemotherapy and radiotherapy. CD30- and PD-1-targeted therapies for CHL do face some challenges. In the relapsed and refractory setting, how to sequence and/or combine these agents remains unclear and requires further investigation. How to combine these agents with chemotherapy also requires further study. With a limited number of eligible patients, carrying out multiple large studies can be difficult. In the frontline setting, a clear role of these agents has yet to be established. While brentuximab vedotin plus chemotherapy is approved for untreated stage III–IV CHL, controversies do exist whether to use this combination for all patients given the small absolute benefit and high cost. The financial cost is a major challenge for all these CD30- and PD-1-targeted therapies in general.

Abbreviations
ABVD: Adriaycin, bleomycin, vinblasteina, dacarbazine; ACRIN: American College of Radiology Imaging Network; ADC: Antibody-drug conjugate; AE: Adverse event; ALCCL: Anaplastic large-cell lymphoma; ALL: Acute lymphoblastic leukemia; ALLO-SCT: Allogeneic stem cell transplantation; ASCT: Autologous stem cell transplantation; ASH: American Society of Hematology; AVD: Adriaycin, vinblasteina, dacarbazine; BEACOPP: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine; prednisone; BECADD: Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; BEPCADD: Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, procarbazine, and prednisone; CAR: Chimeric antigen receptor; CD: Cluster of differentiation; cHL: Classical Hodgkin lymphoma; CMR: Complete metabolic response; CR: Complete response; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; DOR: Duration of response; ECADD: Etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone; ECAP: Etoposide, cyclophosphamide, doxorubicin, procarbazine, and prednisone; ECOG Eastern Cooperative Oncology Group Group; EFS: Event-free survival; EORTC: European Organisation for Research and Treatment of Cancer; ESHAP: Etoposide, Solu-Medrol, high-dose cytarabine, cis-platin; FDA: Food and drug administration; FFS: Failure-free survival; FIL: Fondazione Italiana Linfomi; GELTAMO: Grupo Español de linfomas/ Hematología; HRS: Hodgkin and Reed-Sternberg; ICE: Ifosfamide, carboplatin, etoposide; ISRT: Involved-site radiotherapy; JAK: Janus kinase; Lysa: Lymphoma study association; mAb: Monoclonal antibody; mMel-ED: Monomethyl auristatin E; MR: Minor response; MTD: Maximum tolerated dose; mTOR: Mammalian target of rapamycin; NCCN: National Comprehensive Cancer Network; NLPHL: Nodal lymphocyte predominant Hodgkin lymphoma; ORR: Objective response rate; OS: Overall survival; PD: Progressive disease; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; PD-L2: Programmed death-ligand 2; PET: Positron emission tomography; PFS: Progression-Free survival; PETR: Phosphatidyli-sitol 3 kinase; PR: Partial response; Q2W: Every 2 weeks; Q3W: Every 3 weeks; SD: Stable disease; STAT: Signal transducers and activators of transcription; TNF: Tumor necrosis factor

Acknowledgements
We thank the Media Support Services at Mayo Clinic (Rochester) for their help with illustration.

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.

Authors’ contributions
YW drafted the manuscript. MW, GN, and SA participated in the manuscript preparation and revisions. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. 2Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Received: 12 March 2018 Accepted: 13 April 2018

Published online: 23 April 2018

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30.
2. Diefenbach CS, et al. Hodgkin lymphoma: current status and clinical trial recommendations. J Natl Cancer Inst. 2017;109(d1):dju249.
3. Green MR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosis Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77.
4. Younes A, Ansell SM. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol. 2016;53:186–9.
5. Falini B, et al. In vivo targeting of Hodgkin and Reed-Stemberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol. 1992;82:38–45.
6. Ansell SM, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764–9.
7. Bartlett NL, et al. A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848–54.
8. Forero-Torres A, et al. Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171–9.
9. Falini B, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339:1195–6.
10. Schnell R, et al. A phase I study with an anti-CD30 monoclonal antibody (Ki-4.dgA) in patients with refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8:1779–86.
11. Younes A, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.
12. Fanale MA, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248–55.
13. Ogura M, et al. Phase II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105:840–6.
14. Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.
15. Gopal AK, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236–43.
16. Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562–6.
17. Gopal AK, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012; 120:560–8.
64. Armand P, et al. Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b Keynote-013 Study. Blood. 2016;128:1108.
65. Chen R, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125-32.
66. Chen R, et al. Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed/refractory classical Hodgkin lymphoma (CHL). Hematol Oncol. 2017;35:67.